Christoph A. Umbricht
Villigen, AG 5232, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Developments toward the Implementation of 44Sc Production at a Medical Cyclotron.
Journal: Molecules (Basel, Switzerland)
Published: September 02, 2020
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 21, 2020
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Journal: Theranostics
Published: September 20, 2019
Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617.
Journal: Scientific reports
Published: July 29, 2019
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells.
Journal: The Prostate
Published: April 17, 2019
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 18, 2019
First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 13, 2018
Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for 64Cu-Based PET Imaging.
Journal: Molecular pharmaceutics
Published: October 31, 2018
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Journal: Molecular pharmaceutics
Published: April 24, 2018
Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
Journal: The British journal of radiology
Published: April 17, 2018
Last Updated: 09/26/2026